SpaceX's Falcon Heavy has arrived at its launch pad at the Kennedy Space Center. Will Goodman, Managing Editor at Rockets are Cool, joins Cheddar to discuss what testing the Falcon Heavy will undergo before liftoff in January.
Goodman says the rocket should make it to space by early January, barring any major issues during the testing phase. As for what's on the docket for 2018, Goodman says SpaceX will continue to ramp up efforts for the BFR. He also believes it will add more Falcon 9 launches beyond the three it already has planned for January.
Now Elon Musk had promised to bring two private citizens to the moon in 2018, but will it actually happen? Goodman doesn't believe so, but he has high hopes for the aerospace community in general for the next year...including Blue Origin and Virgin Galatic.
Jill and Carlo talk about optimism on the pandemic and economy, a big demographic shift that will have implications for the midterms, Apple rolling out its new privacy tool, and the Oscars ratings.
Clive McCoy, director of tourism for the British Virgin Islands, joined Cheddar to discuss how the territory was relaxing restrictions for travel to resume back to the tropical getaway.
While much of the world remains hunkered down, the band Six60 has been playing to huge crowds in New Zealand, where social distancing isn’t required after the nation stamped out the coronavirus.
The charitable arm of San Francisco-based technology giant Cisco Systems has pledged to invest $100 million over the next decade to help reverse the impact of climate change.
The White House says the U.S. will begin sharing its entire stock of AstraZeneca COVID-19 vaccines with the world once it clears federal safety reviews.
Officials say the European Union is finalizing plans to allow tourists from the United States to travel to the 27-nation bloc this summer.
Jill is joined by Baker Machado this morning to talk about the CDC reinstating the J&J vaccine, a worsening Coronavirus crisis in India, but also, where things are looking a lot better.
Michigan has become the current national hotspot for COVID-19 infections and hospitalizations at a time when more than half the U.S. adult population has been vaccinated and other states have seen the virus diminish substantially.
A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots.
A growing coalition of private companies, nonprofits, and the federal government are pushing for a more unified approach towards COVID vaccination credentialing.
